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Cancer of the cervix uteri is the second most common cancer in the
world among women and, especially in developing countries, a
major cause of premature death in middle-aged and older women
(Parkin et al, 1993; Pisani et al, 1993). Cytological screening can
reduce morbidity substantially (Hakama, 1982; Pettersson et al,
1985; Anderson et al, 1988; Hakama and Louhivuori, 1988;
Gustafsson and Adami, 1990; Levi et al, 1991; Sigurdsson, 1993),
although in several populations this benefit was limited, occurred
only recently, or could not be demonstrated at all (Villard et al, 1989;
Sasieni, 1991; Gustafsson et al, 1997). In the USA, incidence and
mortality rates of cervical cancer have been declining for several
decades, partly due to PAP-smear screening (Brinton and Fraumeni,
1986; Devesa et al, 1989, 1995). In the UK, mortality rates in
younger birth cohorts are heavily reduced, compared to older
cohorts (Sasieni et al, 1995). Recent reductions in mortality have
been interpreted as benefits from the national screening programme
(Farmery and Gray, 1994; Quinn et al, 1999; Sasieni and Adams,
1999). In Sweden, the introduction of population-based screening
during the 1960s led to a decline in both incidence and mortality
(Pettersson et al, 1985; Gustafsson and Adami, 1990).
The potential of Pap-smear screening to reduce morbidity from
cervix cancer has been documented beyond doubt; however,
important questions remain to be answered. Most analyses were
based on cross-sectional data, i.e. trends in cervix cancer incidence
or mortality were studied according to calendar time, while, in
reality, the effects of screening are linked to birth cohorts. The
reasons for this are threefold: (1) screening is conducted mainly
among women of reproductive ages, i.e. only certain birth cohorts
are affected at a specific point in time; (2) The positive effects of
screening on morbidity and mortality are delayed for 3 years or
more; (3) the benefit of removed precursor lesions may continue
for at least 1 decade. In Sweden, Pap-smear screening was intro-
duced over a relatively short time period and was offered mainly to
young and middle-aged women. Hence, the younger a woman was
during the period when PAP smears came into use, the more exten-
sively she is likely to have been screened during the ages at risk of
developing cancer of the cervix. Analyses allowing estimation of
birth cohort effects should therefore provide more accurate quanti-
tative estimates of effects of screening.
No study has adequately distinguished the effects of screening
on the incidence of squamous cell carcinoma and adenocarcinoma
of the cervix — and the latter may not be preventable at all by PAP
smear screening, since it has no readily detectable preinvasive
stage (Kudo, 1992). The incidence of adenocarcinoma appears to
be increasing in many populations. Failure to take this trend into
account — and, ideally, analyse the incidence of squamous cell
cancer separately — may entail underestimation of the benefit of
detecting and eliminating cancer in situ.
To clarify these issues, we took advantage of certain features
unique to Sweden, including successful nationwide screening
programme, accurate cancer incidence and mortality statistics
during a period of at least 35 years, and separate registration of
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Huddinge, Sweden *Joint first authors.cancer in situ, squamous cell cancer and adenocarcinoma of the
cervix. Our main objectives were: (1) to quantify, by calendar
time, age and birth cohort, the overall trends in cervix cancer
incidence and mortality and (2) to clarify whether screening has
reduced the incidence of adenocarcinoma of the cervix.
SUBJECTS AND METHODS
The Cancer Register and the Death Register
Nationwide cancer registration started in Sweden in 1958.
According to the regulations, all physicians are required to report
all cases of newly diagnosed cancer to the Cancer Registry at the
National Board of Health and Welfare. Pathologists and cytolo-
gists must also notify the Cancer Registry of every cancer diag-
nosis made on surgically removed tissues, biopsies, cytological
specimens and autopsies. Thus, in the majority of cases, the
Registry receives two reports. Cases identified from death certifi-
cates alone are not included in the register (National Board of
Health and Welfare, 1960—1998). In the 1970s the underreporting
of incident cases was estimated at 4.5% and was referable mainly
to patients older than 75 years and those with malignant disease 
of the haematopoietic system (Mattsson and Wallgren, 1984).
Reporting is now considered to encompass close to 100% of 
all diagnosed cases (National Board of Health and Welfare,
1960—1998).
Since 1951, Swedish cause-of-death statistics have been
collected and classified according to the International
Classification of Diseases (ICD). For each death, a death certifi-
cate must be issued by a physician within 1 week. The certificate is
forwarded to Statistics Sweden by the local population registers,
and demographic information is merged with the information on
the death certificate. For each death certificate an underlying cause
of death is selected manually. Any deficit in the register is negli-
gible (National Board of Health and Welfare, 1956—1997). Before
1981 a cancer diagnosis was recorded even if it was considered
only a contributory cause by the certifying physician. In 1981 the
coding routines were changed so that contributory causes of death
were no longer included in the cancer mortality statistics.
In the Swedish Cancer Registry, all tumours are coded
according to the ICD-7 and according to histopathological type.
Cancer of the cervix uteri, squamous cell cancer and adenocarci-
nomas, as well as adeno-squamous carcinomas, have separate
codes in the Registry.
The adeno-squamous carcinomas, a rare histopathological type,
were not included in our analyses since their incidence has
remained stable during the period of study. The Cancer Registry
also requires the reporting of cancer in situ and severe dysplasia,
which is on the borderline of cancer in situ (National Board of
Health and Welfare, 1984); we refer to these lesions as cancer in
situ of the cervix.
Our analysis was based on 110 653 patients diagnosed as having
cervix cancer in situ, 21805 invasive squamous cell cancers and
2584 adenocarcinomas about which the Cancer Registry was noti-
fied during the period 1958—1995; and also 10 655 patients who
had invasive cervical cancer coded as their cause of death between
1953 and 1995. However, in the age-period cohort modelling
(see below) the study period end 1992, since we divided the data in
5-year calendar time periods.
Screening for cervical cancer
Pap-smear screening was introduced in Sweden firstly on a small
scale with testing of possibly symptomatic women. In 1963 about
200 000 smears were taken annually, while in 1970 the figure 
had increased to about 1 000 000 (National Board of Health and
Welfare, 1982). Population-based screening programmes, where
women were actively invited for screening, were introduced
between 1967 and 1973, except for the city of Gothenburg where
an organized screening programme was not begun until 1977
(National Board of Health and Welfare, 1976). All women aged
30—49 years were then invited to undergo an examination at 4-year
intervals. Later on, women 25 years of age or more were also
invited to participate and the screening interval was shortened to 3
years, although this policy varied somewhat with time and place.
When screening was fully implemented in Sweden around one-
quarter of the smears were taken in the organized screening
programmes, and the remaining three-quarters were taken at
hospitals and outpatient clinics through opportunistic testing
(National Board of Health and Welfare, 1982; Pettersson et al,
1985; Gustafsson et al, 1995b).
Statistical methods
Incidence and mortality rates were standardized to the Swedish
census population in 1970 (National Board of Health and Welfare,
1960—1998). We performed simple trend-analyses for 5-year age-
specific rates, as well as for age-standardized rates. We used a
model that implied a constant annual relative change in rates by
regressing logarithmic rates on linear trend variables. Such trend
analyses were also performed for subperiods to allow for changes
in growth rates. For simplicity we used the same cut-off year
(1968) in these analyses, although this need not be absolutely
optimal in all instances. Models including second-order trend
terms were also estimated to accommodate non-linear effects and
to test the assumption of the basic linear model.
We based age-period cohort analyses of incidence rates on
grouped 5-year data comprising 13 age-classes (20—24, ￿, 80—84
years) and seven time periods when the cancers were diagnosed
(1958—1962, ￿, 1988—1992), which consequently meant 19
partially overlapping birth cohorts (1874—1882, 1879—1887, ￿,
1964—1972). Correspondingly, mortality rates were analysed from
1953—1957 to 1988—1992, with 20 partially overlapping birth
cohorts. To obtain the effects of age, period and cohort on cancer
incidence and mortality, models were fitted on the assumption that
the number of cases constituted a variable with a Poisson distribu-
tion. The effects of age, period and cohort were assumed to be
multiplicative, and the parameters of the models were estimated by
means of the maximum likelihood method using generalized linear
models. Results are presented as relative risks (RR) with 95%
confidence intervals (CI). To judge the plausibility of the assump-
tion that the relative differences between birth cohorts are the same
at different ages we also estimated separate age-cohort models for
various broader age-classes where needed.
A large number of observed cases may cause overdispersion
(Breslow, 1984), i.e. if the assumption of a Poisson distribution is
true, the unexplained variance is larger than expected, without 
any apparent misspecification of the model. Such results were
obtained in several instances; the deviance of the full age-period-
cohort model being considerably larger than the degrees of
freedom. The overdispersion made it unsuitable to employ tests
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by Breslow (1984) to adjust for the overdispersion, it gave
parameter estimates close to the standard maximum likelihood
estimates of the Poisson model without this adjustment. Therefore,
only risk estimates from the standard model are shown with
standard errors adjusted for overdispersion. In the testing of
different models, F-tests were performed to allow for the over-
dispersion.
RESULTS
Cancer in situ
The reported annual incidence of cancer in situ in Sweden before
1960 was low, the age-standardized rate in 1958—1959 being about
five cases per 105. Following the introduction of screening, the
reported incidence increased about 20-fold to 100 per 105 in 1968.
This level, sustained for a few years, declined slowly to about 90
per 105 in the mid-1980s (Figure 1).
To describe the trend-wise development by age, we estimated
separate models for periods before and after the introduction of
widespread screening, i.e. 1958—1967 and 1968—1995. As shown
in Table 1, the increasing trend during the 1958—1967 period was
marked in all age-classes. The growth rate was fastest for women
aged 20—24 years and diminished with increasing age. Starting in
1968 and thereafter, there were slight decreases in the reported
incidence for young and middle-aged women (Table 1). The
significant second-order terms for these groups reflect an initial
increase up until the beginning of the 1980s for younger women
and then a subsequent decrease (negative terms), while for middle-
aged women it reflects a rapid decrease during the first few years
after 1968 that gradually slowed down (positive terms).
Age-period-cohort modelling based on the period 1958—1992
using the Poisson distribution revealed that the age-period model
was clearly superior to the age-cohort model, although the former
was inferior to the full age-period-cohort model. The deviance of
this model was much larger than the degrees of freedom, indi-
cating either a poorly fitting model and/or overdispersion. An
analysis confined to the period 1968—1992 still indicated the age-
period model as the preferred one, since the age-period-cohort
model was superior neither to the age-period model nor to the age-
cohort model (Table 2). Considerable overdispersion still
remained.
Squamous cell carcinoma
The age-standardized incidence of squamous cell carcinoma did
not change significantly during the period 1958—1967. Only
women aged 35—39 years had a growth rate significantly different
from null, with an average annual decrease of 2.6% (Table 1).
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Figure 1 Trends in age-standardized incidence rates of cancer in situ,
squamous cell cancer and adenocarcinoma of the cervix uteri in Sweden,
1958–1995, obtained from the Cancer Registry (National Board of Health
and Welfare, 1960–1998); and mortality rates from invasive cervical cancer in
Sweden, 1953–1992, obtained from the Death Registry (National Board of
Health and Welfare, 1956–1997)
Table 1 Mean annual percentage change in age-specific and age-standardized incidences of reported cancer in situ (CIS), squamous cell cancer and
adenocarcinoma of the cervix, 1958–1995, and in mortality from cancer of the cervix, 1953–1995, in Swedena
CIS Squamous cell cancer Adenocarcinoma Mortality
1958–1967 1968–1995 1958–1967 1968–1995 1958–1995 1953–1967 1968–1995
Age-class % % Second % % Second % Second % % Second
Order Order Order Order
termc termc termc termc
20–24 51.7*** –1.3** –*** –4.7 –1.9 –** NAb NAb NAb
25–29 48.4*** –0.1* –*** –5.3 –1.7** –*** 3.1*** – NAb NAb
30–34 45.3*** –2.1*** –*** 0.8 –1.5*** – 3.6*** – –0.8 –3.6** –
35–39 39.9*** –2.4*** – –2.6* –2.7*** +*** 2.5*** + 2.7 –3.0** +*
40–44 36.8*** –2.4*** + 1.6 –4.2*** +** 1.4 – 3.5* –6.1*** +*
45–49 36.7*** –2.6*** +** 1.1 –5.5*** +*** 1.4 + 7.3*** –7.0*** +
50–54 35.5*** –1.2** +*** 1.7 –5.5*** +*** 1.0 – 4.4** –6.1*** +
55–59 31.7*** –0.5 +*** –1.6 –5.8*** +*** 1.1 – 4.3** –6.2*** –
60–64 37.3*** –0.9* +* –1.8 –5.2*** – 1.8* + 3.8* –4.1** –
65–69 21.5* 0.7 +* 1.8 –2.5*** – 2.1* – 2.0* –2.7*** –***
70–74 18.4** 1.5* +* 1.6 –2.1*** + 2.0* – 2.0 –2.7*** –
75–79 NAb 2.6 + 4.0 0.6 – 0.3 – 5.6* –1.6** –
80–84 NAb 0.1 + 4.1 –1.7** – 1.3 – 3.2 –0.8 –
85+ NAb NAb –0.2 –0.1 – –0.4 – 1.6 –0.2 –
Age standardized 40.7*** –1.7*** –** 0.3 –3.7*** +*** 1.8*** – 3.6*** –4.0*** –
a *P < 0.05, **P < 0.01, ***P < 0.001; b too few observations; c sign + or– and P-value.During 1968—1995, on the other hand, the age-standardized figure
declined from 20 cases per 105 in 1968 to around seven per 105 in
1995 (Figure 1). This implied an average annual reduction of
3.7%, with marked differences between age-classes. The largest
reduction occurred among middle-aged women, with an annual
decrease of 4—6% for 40—64-year-old women. Among younger
and older women the decrease gradually became lower, and in the
youngest and oldest age-classes there was no significant average
change (Table 1). The significant negative second-order terms in
the two youngest age-classes reflect an initial increase in incidence
and a later decrease from the mid 1980s. Among middle aged
women the decline was rapid during the first few years after 1968
and then slowed down or ceased.
Age-period-cohort modelling of incidence data for squamous
cell cancer during the entire period 1958—1992 did not produce an
acceptable model fit. Systematic errors reflected a structural break
following the introduction of screening. A modelling based on the
period 1968—1992 produced more satisfactory results. Some
overdispersion still occurred (deviance 97.23 on 33 degrees of
freedom) and the age-cohort model was vastly superior to the age-
period model (Table 2). The age-period-cohort model was not an
improvement over the age-cohort model (P = 0.13).
We found a pronounced birth cohort pattern with little differ-
ence between the oldest cohorts followed by a monotonous decline
among women born between 1913 and 1938 (Figure 2). The inci-
dence relative to the reference birth cohort 1923 decreased from
1.86 in 1913 to 0.27 for the 1943 cohort. For younger cohorts the
relative reduction in incidence remained fairly stable at 70—75%,
without any evidence of increase in the youngest birth cohorts
(Table 3). When we separated the birth cohort effects on various
age classes (< 60, 60+; < 50, 50+; < 40, 40+; < 40, 40—60, 60+)
virtually the same pattern over birth cohorts emerged. The steepest
decline in relative risk was seen for ages 40—60 over the birth
cohorts 1913—1943.
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Table 2 Results of fitting Poisson regression models to incidence of reported cancer in situ (CIS), 1968–1992, squamous cell cancer, 1968–1992, and
adenocarcinoma, 1958–1992
Model CIS Squamous cell cancer Adenocarcinoma
d.f Deviancea P-valueb d.f. Deviancea P-valueb d.f. Deviancea P-valueb
Age 52 2191.89 52 1536.63 78 221.47
Age+drift 51 1204.12 51 523.29 77 126.89
Age+period 48* 1080.39 0.52 48 491.67 <0.001 72* 109.36 0.11
Age+cohort 36 890.35 0.14 36* 115.26 0.13 60 91.41 0.03
Age+period+cohort 33 756.37 33 97.23 55 73.90
d.f. Degrees of freedom; aDeviance from the standard Poisson model; bP-value based on test with F-statistic. Compares partial model with the full age-period-
cohort model. The asterisk indicates the best fitting model used to estimate effects shown in Table 3.
Table 3 Relative risks (RR) with 95% confidence intervals (CI) for incidence of reported cancer in situ (CIS), squamous cell cancer and adenocarcinoma; and
for mortality from cervix cancer, for selected time periods and birth cohorts
Determinant CIS Squamous cell cancer Adenocarcinoma Mortality
RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Birth cohorta
1903 2.07 1.70–2.51 1.72 1.48–2.00
1908 2.02 1.70–2.39 1.67 1.46–1.91
1913 1.86 1.60–2.16 1.58 1.39–1.78
1918 1.49 1.29–1.71 1.31 1.17–1.47
1923 1.00 Reference 1.00 Reference
1928 0.68 0.59–0.79 0.71 0.62–0.81
1933 0.45 0.38–0.53 0.47 0.40–0.55
1938 0.32 0.26–0.38 0.34 0.29–0.41
1943 0.27 0.23–0.33 0.21 0.17–0.27
1948 0.26 0.21–0.32 0.24 0.19–0.30
1953 0.26 0.21–0.33 0.21 0.16–0.29
1958 0.24 0.18–0.32 0.19 0.12–0.28
1963 0.22 0.15–0.32 0.20 0.11–0.36
Time period
1953–1957 0.67 0.60–0.75
1958–1962 0.72 0.57–0.90 1.01 0.91–1.11
1963–1967 1.01 0.83–1.24 1.00 Reference
1968–1972 1.00 Reference 1.00 Reference
1973–1977 0.88 0.80–0.96 0.92 0.75–1.13
1978–1982 0.89 0.81–0.98 1.16 0.95–1.41
1983–1987 0.82 0.75–0.90 1.42 1.18–1.71
1988–1992 0.71 0.64–0.79 1.45 1.20–1.74
aCentral year of birth, e.g. 1898 refers to women born 1894–1902. All birth cohorts not shown. Estimates obtained from best fitting models, as indicated in
Tables 2 and 4.Adenocarcinoma
The age-standardized incidence of invasive adenocarcinoma
increased substantially from 1958 to 1995 (Figure 1), on average
by 1.8% annually. This growth was due to increases in incidence
among women of all ages, most pronounced for ages 25—39. There
were no significant second-order terms, indicating consistency in
growth rates during the study period (Table 1). Adenocarcinomas
accounted for 4.8% of all invasive cervical cancers in 1958 and for
19% in 1995.
Age-period-cohort modelling showed that there was not a great
difference between the fits of the age-period and the age-cohort
model (Table 2). Since the age-period-cohort model was signifi-
cantly better than the age-cohort model, but not better than the 
age-period model, we chose the age-period model as a valid
description of our data. The whole study period 1958—1992 could
be used as the basis for a model that gave an acceptable fit to the
data. We found a continuous increase in RR from the first to the
last time period, with a doubling of the incidence over the 35 years
of the study (Table 3).
Mortality
During the 1950s the age-standardized mortality from cervical
cancer increased from around four per 105 in 1953 to around eight
per 105 in 1960. This level was maintained until about 1970, when
a steady decrease started (Figure 1). In 1990 the age-standardized
mortality rate was well under four per 105, an average decrease of
4.0% annually from 1968 to 1995. The fastest decrease took place
at ages 40—59 years, with a yearly average of 6—7%. At younger
and older ages the decrease was slower, with no significant
changes in the youngest and oldest age-classes. There were few
significant second order terms, indicating limited changes in
growth rates during the period 1968—1995 (Table 1).
Age-period-cohort modelling yielded more satisfactory results
when the two time periods 1953—1967 and 1968—1992 were
analysed separately rather than together. Two different patterns
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Table 4 Results of fitting Poisson regression models to mortality data for cervix cancer for different time periods
1953–1967 1968–1992
Model d.f. Deviancea P-valueb d.f. Deviancea P-valueb
Age 26 162.31 52 624.59
Age+drift 25 80.80 51 208.67
Age+period 24* 44.17 0.13 48 207.06 <0.001
Age+cohort 12 47.17 <0.001 36* 43.67 0.83
Age+period+cohort 11 13.07 33 42.53
d.f. Degrees of freedom; aDeviance from the standard Poisson model  b P-value based on test with F-statistic. Compares partial
model with the full age-period-cohort model. The asterisk indicates the best fitting model used to estimate effects shown in Table 3.
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Figure 2 Relative risks of squamous cell cancer incidence in Sweden by
birth cohort according to the age-cohort model for the period 1968–1992,
specified in Table 2
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Figure 3 Age-specific incidence of squamous cell cancer of the cervix uteri
in Sweden 1958–1992, by birth cohortemerged (Table 4). The first time period could best be described by
an age-period model, since the full age-period-cohort model was
not an improvement over the age-period, but it was an improve-
ment over the age-cohort model. For 1968—1992, the age-cohort
model was an adequate representation of the data, since the full
age-period-cohort model led to little further reduction in deviance
and there was little evidence of overdispersion. For this time span
the age-period model did not give a satisfactory representation of
the data (Table 4).
In the period 1953—1967 the mortality rate was significantly
lower (RR = 0.67) than that in the period 1963—1967. The birth
cohort effects obtained from the age-cohort model during
1968—1992 were similar to those obtained for squamous cancer
incidence (Table 3). There was little change among the oldest
cohorts, while a rapid reduction in RR took place among birth
cohorts born from 1913 to 1943, the RR of the latter being 0.21
with the 1923 cohort as reference. Among younger cohorts there
was no further reduction, nor any evidence of increase in risk
(Table 3). Estimation of birth cohort effects for mortality on the
basis of restricted age classes produced a pattern similar to that for
squamous cancer incidence.
DISCUSSION
Our study covers a time period when an extensive prevention
programme for cancer of the cervix was implemented in Sweden.
This initiative followed successful efforts toward early detection
and improved treatment of invasive cancer dating back to the first
decades of this century (Pont￿n et al, 1995; Spar￿n et al, 1995). An
organized programme (e.g. an active invitation to women for
screening), coupled with an expansion of cytological laboratory
services, were the means through which this intervention was
carried out. However, there was also an awareness that oppor-
tunistic testing complemented the intervention programme; its
expansion was indeed encouraged (National Board of Health and
Welfare, 1970). In the 1970s and thereafter, when the screening
programme was fully implemented, only about one-quarter of the
smears were taken under the auspices of the organized screening
programme, while the remaining three-quarters represented oppor-
tunistic screening, i.e. smears taken at hospitals, maternal health
care units and other outpatient clinics (National Board of Health
and Welfare, 1982; Pettersson et al, 1985; Gustafsson et al,
1995b).
The incidence and mortality pattern of cervical cancer was
completely changed within a period of 10 years. After a substantial
initial increase in the reported incidence of cancer in situ — though
smaller for older women (Table 1) — the rates remained fairly
stable thereafter. This indicates that the screening activities
continued with full force (Figure 1). The overall incidence of and
mortality from invasive cervical cancer decreased gradually, as
reported earlier in Sweden (Pettersson et al, 1985; Gustafsson and
Adami, 1990) and other countries (Hakama, 1982; Anderson et al,
1988; Hakama and Louhivuori, 1988; Levi et al, 1991;
Sigurdsson, 1993).
The observed changes in incidence pattern were, however, not
uniform for squamous cell cancer and adenocarcinoma. Trends in
squamous cell cancer incidence could best be described as a cohort
phenomena with three phases: while the oldest cohorts were not
influenced by screening, women born between 1918 and 1938
experienced an increasingly large benefit and in more recent
cohorts the reduction in incidence gradually levelled off (Figure
2). In fact, a reduction could be seen even among women born
during the first 2 decades of this century (Figure 3). However, this
could hardly be ascribed to the introduction of the screening
programme in the mid-1960s, since these women were 50 years or
older when large-scale screening started in Sweden. The reduction
in incidence of squamous cell cancer caused a subsequent reduc-
tion of mortality for cervical cancer among the birth cohorts
reflected (Table 3).
A different development was seen for adenocarcinomas of the
cervix, namely a continuing increase in incidence affecting all
ages, but particularly younger women. The relative risk, signifi-
cantly lower during the first time period 1958—1962 compared to
the reference period (1968—1972), levelled off between 1963 and
1977 and increased again through 1992 (Table 3). The incidence of
adenocarcinoma seemed to be unaffected by screening, although
screening might improve the prognosis of the disease due to detec-
tion at earlier stages (Sigurdsson, 1993). A recent study using
SEER data, reported the increase of adenocarcinoma in US white
women as a birth cohort phenomenon (Zheng et al, 1996). We
could not find support for a cohort effect being more important
than the period effect described above in the present data set.
Other reports of increasing incidence of cervical cancer among US
white women below the age of 50 are present (Larsen, 1994). No
systematic review of histologies from the 1960s, to see if some of
the old squamous cell tumours would now be classified as adeno-
carcinomas, was performed. To our knowledge there were no
major changes in the classification of histology of cervical cancer
tumours.
When interpreting the results of an age-period-cohort model-
ling, it is important to be aware of the fundamental problems
caused by the linear dependence between the linear age, period
and cohort effects. The non-linear effects, on the other hand, are
uniquely defined, but a meaningful interpretation requires that the
linear effects be included (Clayton and Schifflers, 1987a, 1987b;
Holford, 1991; Tarone and Chu, 1996); for further discussion see
Adami et al (1993a, 1993b). In none of the instances considered
here (different histological categories and mortality) was the full
age-period-cohort model a significant improvement over the best
partial model. This meant that we did not try to find a solution to
the identification problem of the full model, as the best partial
model could be used. Contrary to what is sometimes believed, the
fact that the age-cohort model contains more terms than the age-
period model is not a problem, as the formal testing procedure
takes account of the number of degrees of freedom.
A basic assumption underlying the age-period-cohort model is
that the incidence rate depends multiplicatively on age, period
and/or cohort. Among other things this means that in a model
which includes cohort effects, the relative difference between birth
cohorts is assumed to be the same at all ages. However, typically
we only have observations for a given birth cohort over a limited
number of age-classes. Thus, the oldest cohorts are only observed
at old ages, while the most recent ones are only observed at young
ages. This makes it difficult to judge whether the assumption of
multiplicativity is reasonable. It also means that if the relative risk
differences between cohorts were to change with age, the results of
a cohort modelling might not be completely reliable. If, for
example, the cohort effects are less pronounced at high ages, the
cohort effects obtained from an age-cohort model may exaggerate
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website: www.grace.se/￿shprsn/cervix.htmthe life-time reduction in risk for recent cohorts. When we
separated the birth cohort effects on different age-classes, the over-
lapping of birth cohorts between ages was too small to make
formal testing suitable. Since we cannot be sure that the assump-
tion of multiplicativity between old and recent birth cohorts holds
true, we need to interpret results about the magnitude of risk reduc-
tion with some caution.
The reduction in incidence of squamous cell cancer and
mortality by 70—75% in more recent birth cohorts extends observa-
tions in previous studies (Pettersson et al, 1985; Gustafsson and
Adami, 1990). We followed women born as late as the 1960s to
elucidate if the positive effects of screening were maintained in
younger birth cohorts. The levelling off of the risk for incidence of
squamous cell cancer and mortality, starting from the 1943 and
1948 cohorts, respectively, indicates that the number of incident
cases detected each year has entered a ￿steady state￿ in the birth
cohorts concerned.
If, as reported from the USA (Larsen, 1994; Weiss et al, 1994),
Australia (Armstrong and Holman, 1981; Bourne and Grove,
1983) and Europe (Beral, 1984; Levi et al, 1989; Macgregor et al,
1994), there is an increasing trend of cervical cancer among
younger women, possibly due to changes in sexual habits and
increased transmission of human papilloma viruses, this trend
would most likely also exist in Sweden. Our results indicate that
screening so far has counteracted such a trend of squamous cell
cancer, since we found no evidence of an increasing trend among
younger birth cohorts. The high incidence of cervical cancer in
women over 60 years of age in many screened populations today
most likely depends on insufficient screening at younger ages.
Thus, in the future one would expect reduced incidence rates of
squamous cell cancer among older women as the cohorts that have
been screened since age 20 or 30 become older (Figure 3).
Intensified screening of older women does not necessarily reduce
the incidence of squamous cell cancer. In a previous study we
found strong indications that, apart from a lower prevalence of
premalignant lesions at older ages, screening is less likely to detect
precursors of cervical cancer among older women (Gustafsson et
al, 1995a).
The continuous increase in the incidence of adenocarcinoma
during the period of study indicates that the incidence of adeno-
carcinoma of the cervix is not affected by screening. This was also
the conclusion of a recent case control study (Mitchell et al, 1995).
Comparable increases have been reported in other populations
(Bj¿rge et al, 1993; Kruger Kjaer and Brinton, 1993; Miller et al,
1993; Sigurdsson, 1993). The increase among women aged 25—39
years, although from a low level, is alarming. Adenocarcinoma of
the cervix seems to entail a poorer prognosis than squamous cell
cancers, also when controlling for clinical stage at diagnosis
(Milsom and Friberg, 1983; Silcocks et al, 1987; Pengsaa et al,
1989; Hopkins and Morley, 1991; Sigurdsson et al, 1991; Kudo,
1992; Bj¿rge et al, 1993). It accounts for an increasingly higher
proportion of the incident cervical cancers due to the underlying
growth rate of the disease and the diminishing incidence of
squamous cell cancer. The rapid growth rate of adenocarcinomas
among younger women might contribute to the increasing inci-
dence of cervical cancer among younger women recently reported.
In Sweden, a combination of organized and opportunistic
screening seem to have reduced the incidence of squamous cell
cancer in the most screened cohorts by around 70%. A prerequisite
for this successful combination was the planned expansion of labo-
ratory services and a strict follow-up of all abnormal tests,
managed in part by the hospital laboratories themselves. In spite of
this, the incidence of adenocarcinoma seems unaffected and is
indeed increasing. New screening methods need to be developed
to detect microinvasive adenocarcinoma as well as precursors of
squamous cell cancer among older women.
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